Valneva Announces the Availability of Documentation for its Extraordinary General Meeting including Planned Changes to its Future Board of Directors
15 November 2023 - 5:30PM
Valneva Announces the Availability of Documentation for its
Extraordinary General Meeting including Planned Changes to its
Future Board of Directors
Saint-Herblain (France), November 15, 2023 –
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine
company, today announced the availability of documentation for its
Extraordinary General Meeting (“General Meeting” or “EGM”) which
will be held on December 20, 2023 at 2:00 p.m. CET at the Radisson
Blu Hotel, 6 place Aristide Briand, 44000 Nantes, France.
As announced in June 20231, during this EGM,
shareholders will notably vote on the Supervisory Board’s
recommendation to transition from the Company’s current two-tier
governance model, which includes a Supervisory Board and a
Management Board, to a one-tier model led by a Board of
Directors.
As part of the proposed changes, three current
Supervisory Board members will not join the future Board of
Directors, Ms. Johanna Pattenier, Ms. Sharon Tetlow and Mr.
Frederic Grimaud, current Chairman of the Supervisory Board.
“It has been a huge endeavor as well as a real
pleasure to be part of the Valneva journey to build an innovative
and recognized new player in the vaccine industry. After ten years
of chairmanship, I feel it is time for me to step aside, and the
change in governance model provides a good opportunity to do this.
As shareholders of Valneva, Groupe Grimaud and I will continue to
follow the Company’s progress, especially as its two lead programs
against chikungunya and Lyme disease are reaching important
catalysts. I wish Valneva every success in the future,”
said Frederic Grimaud, Valneva’s Chairman of the Board and
Groupe Grimaud’s President and Chief Executive
Officer.
The future Board of Directors is expected to
elect a new chairperson during its constitutional post EGM meeting.
The Company also intends to propose additional, complementary Board
of Directors members to its shareholders at its Annual General
Meeting in June 2024.
Thomas Lingelbach, Chief Executive
Officer of Valneva, commented, “As Valneva continues to
grow, we believe that adopting a governance model that is more
common in our industry will allow us to further improve the
effectiveness and efficiency of the Company leadership. I would
like to thank Frederic for his commitment as a co-founder of
Valneva and his dedication over the past ten years, as well as
Johanna and Sharon for their valuable support since 2020.”
All documents and information related to the
General Meeting are available on the Company’s website at
https://valneva.com/december-20-2023-combined-general-meeting/.
The Preliminary Notice of Meeting – including
the agenda, the draft resolutions proposed by the Management Board
and the modalities of participation – will be published in the
Bulletin des Annonces Légales Obligatoires (BALO).About
Valneva SEWe are a specialty vaccine company that
develops, manufactures, and commercializes prophylactic vaccines
for infectious diseases addressing unmet medical needs. We take a
highly specialized and targeted approach, applying our deep
expertise across multiple vaccine modalities, focused on providing
either first-, best- or only-in-class vaccine solutions.
We have a strong track record, having advanced
multiple vaccines from early R&D to approvals, and currently
market two proprietary travel vaccines as well as certain
third-party vaccines leveraging our established commercial
infrastructure.
Revenues from our growing commercial business
help fuel the continued advancement of our vaccine pipeline. This
includes the only Lyme disease vaccine candidate in advanced
clinical development, which is partnered with Pfizer, potentially
the world’s first vaccine against the chikungunya virus, as well as
vaccine candidates against the Zika virus and other global public
health threats.
Valneva
Investor and Media ContactsLaetitia Bachelot-FontaineVP
Global Communications & European Investor RelationsM +33 (0)6
4516
7099laetitia.bachelot-fontaine@valneva.com |
Joshua
Drumm, Ph.D.VP Global Investor RelationsM +001 917 815
4520joshua.drumm@valneva.com |
Forward-Looking Statements
This press release contains certain
forward-looking statements relating to the business of Valneva. In
addition, even if the actual results or development of Valneva are
consistent with the forward-looking statements contained in this
press release, those results or developments of Valneva may not be
sustained in the future. In some cases, you can identify
forward-looking statements by words such as “could,” “should,”
“may,” “expects,” “anticipates,” “believes,” “intends,”
“estimates,” “aims,” “targets,” or similar words. These
forward-looking statements are based largely on the current
expectations of Valneva as of the date of this press release and
are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievement expressed or implied by
these forward-looking statements. In particular, the expectations
of Valneva could be affected by, among other things, uncertainties
and delays involved in the development and manufacture of vaccines,
unexpected clinical trial results, unexpected regulatory actions or
delays, competition in general, currency fluctuations, the impact
of the global and European credit crisis, and the ability to obtain
or maintain patent or other proprietary intellectual property
protection. Success in preclinical studies or earlier clinical
trials may not be indicative of results in future clinical trials.
In light of these risks and uncertainties, there can be no
assurance that the forward-looking statements made during this
presentation will in fact be realized. Valneva is providing the
information in these materials as of this press release and
disclaim any intention or obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise.
1 Valneva Supervisory Board Recommends Transition from a
Two-Tier Governance Model to a Board of Directors - Valneva
- 2023_11_15_Availability of Documentation_EGM_PR_EN_Final
Valneva (LSE:0OB3)
Historical Stock Chart
From May 2024 to Jun 2024
Valneva (LSE:0OB3)
Historical Stock Chart
From Jun 2023 to Jun 2024